This weekend brings you “Knight at Dawn: Kids” a play that follows time-traveling kids to medieval times, and an all-time classic “Romeo and Juliet.” Or indulge your creative side at the popular ...

Academic posters are a great way to convey your research to an audience. By following a few simple rules most common design blunders can be avoided. In this course you will learn how to structure and ...

As per a press release, the trailer of Romeo S3 offers an exciting glimpse into the gritty, high-stakes world of Romeo S3. DCP Sangram Singh Shekhawat, played by Thakur Anoop Singh, is a cop ...

But Ashton’s “Romeo and Juliet” – the first ballet interpretation of Shakespeare’s familiar story created in the West, without influence from the original 1940 Soviet version by Leonid ...

today announced upcoming poster presentations including one for CM24 in the treatment of pancreatic cancer, and two for NT219 in the treatment of colorectal and head and neck cancers, at the 2025 ...

Gain Therapeutics' lead drug candidate, GT-02287, is in clinical development for the treatment of Parkinson's disease (PD) with or without a GBA1 mutation. The orally administered, brain-penetrant ...

today announced upcoming poster presentations including one for CM24 in the treatment of pancreatic cancer, and two for NT219 in the treatment of colorectal and head and neck cancers, at the 2025 ...

“It’s Romeo and Juliet, right? House divided. The characters have such histories,” Tom said of the dueling families. “You have decades and decades and decades of history to be played and ...

Erasca will also present potential first-in-class examples of direct SMP complex inhibitors, representing a new approach to block the RAS/MAPK pathway SAN DIEGO, March 25, 2025 (GLOBE NEWSWIRE) -- ...

The company will deliver an oral presentation on ADRX-0405, its clinical-stage STEAP1 ADC, and a poster presentation on ADRX-0134, its preclinical NaPi2b ADC. The presentations will underscore the ...

SAN DIEGO, March 25, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies ...